1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Gene Therapy for Age-related Macular Degeneration Market Size Growth Rate by Type: 2018 VS 2022 VS 2029 1.2.2 Subretinal 1.2.3 Intravitreal 1.3 Market by Application 1.3.1 Global Gene Therapy for Age-related Macular Degeneration Market Growth by Application: 2018 VS 2022 VS 2029 1.3.2 Monotherapy 1.3.3 Combination Therapy 1.4 Study Objectives 1.5 Years Considered 1.6 Years Considered 2 Global Growth Trends 2.1 Global Gene Therapy for Age-related Macular Degeneration Market Perspective (2018-2029) 2.2 Gene Therapy for Age-related Macular Degeneration Growth Trends by Region 2.2.1 Global Gene Therapy for Age-related Macular Degeneration Market Size by Region: 2018 VS 2022 VS 2029 2.2.2 Gene Therapy for Age-related Macular Degeneration Historic Market Size by Region (2018-2023) 2.2.3 Gene Therapy for Age-related Macular Degeneration Forecasted Market Size by Region (2024-2029) 2.3 Gene Therapy for Age-related Macular Degeneration Market Dynamics 2.3.1 Gene Therapy for Age-related Macular Degeneration Industry Trends 2.3.2 Gene Therapy for Age-related Macular Degeneration Market Drivers 2.3.3 Gene Therapy for Age-related Macular Degeneration Market Challenges 2.3.4 Gene Therapy for Age-related Macular Degeneration Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Gene Therapy for Age-related Macular Degeneration Players by Revenue 3.1.1 Global Top Gene Therapy for Age-related Macular Degeneration Players by Revenue (2018-2023) 3.1.2 Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Players (2018-2023) 3.2 Global Gene Therapy for Age-related Macular Degeneration Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.3 Players Covered: Ranking by Gene Therapy for Age-related Macular Degeneration Revenue 3.4 Global Gene Therapy for Age-related Macular Degeneration Market Concentration Ratio 3.4.1 Global Gene Therapy for Age-related Macular Degeneration Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Gene Therapy for Age-related Macular Degeneration Revenue in 2022 3.5 Gene Therapy for Age-related Macular Degeneration Key Players Head office and Area Served 3.6 Key Players Gene Therapy for Age-related Macular Degeneration Product Solution and Service 3.7 Date of Enter into Gene Therapy for Age-related Macular Degeneration Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Gene Therapy for Age-related Macular Degeneration Breakdown Data by Type 4.1 Global Gene Therapy for Age-related Macular Degeneration Historic Market Size by Type (2018-2023) 4.2 Global Gene Therapy for Age-related Macular Degeneration Forecasted Market Size by Type (2024-2029) 5 Gene Therapy for Age-related Macular Degeneration Breakdown Data by Application 5.1 Global Gene Therapy for Age-related Macular Degeneration Historic Market Size by Application (2018-2023) 5.2 Global Gene Therapy for Age-related Macular Degeneration Forecasted Market Size by Application (2024-2029) 6 North America 6.1 North America Gene Therapy for Age-related Macular Degeneration Market Size (2018-2029) 6.2 North America Gene Therapy for Age-related Macular Degeneration Market Growth Rate by Country: 2018 VS 2022 VS 2029 6.3 North America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2018-2023) 6.4 North America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2024-2029) 6.5 United States 6.6 Canada 7 Europe 7.1 Europe Gene Therapy for Age-related Macular Degeneration Market Size (2018-2029) 7.2 Europe Gene Therapy for Age-related Macular Degeneration Market Growth Rate by Country: 2018 VS 2022 VS 2029 7.3 Europe Gene Therapy for Age-related Macular Degeneration Market Size by Country (2018-2023) 7.4 Europe Gene Therapy for Age-related Macular Degeneration Market Size by Country (2024-2029) 7.5 Germany 7.6 France 7.7 U.K. 7.8 Italy 7.9 Russia 7.10 Nordic Countries 8 Asia-Pacific 8.1 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size (2018-2029) 8.2 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Growth Rate by Region: 2018 VS 2022 VS 2029 8.3 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size by Region (2018-2023) 8.4 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size by Region (2024-2029) 8.5 China 8.6 Japan 8.7 South Korea 8.8 Southeast Asia 8.9 India 8.10 Australia 9 Latin America 9.1 Latin America Gene Therapy for Age-related Macular Degeneration Market Size (2018-2029) 9.2 Latin America Gene Therapy for Age-related Macular Degeneration Market Growth Rate by Country: 2018 VS 2022 VS 2029 9.3 Latin America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2018-2023) 9.4 Latin America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2024-2029) 9.5 Mexico 9.6 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size (2018-2029) 10.2 Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Growth Rate by Country: 2018 VS 2022 VS 2029 10.3 Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size by Country (2018-2023) 10.4 Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size by Country (2024-2029) 10.5 Turkey 10.6 Saudi Arabia 10.7 UAE 11 Key Players Profiles 11.1 RetroSense Therapeutics 11.1.1 RetroSense Therapeutics Company Detail 11.1.2 RetroSense Therapeutics Business Overview 11.1.3 RetroSense Therapeutics Gene Therapy for Age-related Macular Degeneration Introduction 11.1.4 RetroSense Therapeutics Revenue in Gene Therapy for Age-related Macular Degeneration Business (2018-2023) 11.1.5 RetroSense Therapeutics Recent Development 11.2 REGENXBIO 11.2.1 REGENXBIO Company Detail 11.2.2 REGENXBIO Business Overview 11.2.3 REGENXBIO Gene Therapy for Age-related Macular Degeneration Introduction 11.2.4 REGENXBIO Revenue in Gene Therapy for Age-related Macular Degeneration Business (2018-2023) 11.2.5 REGENXBIO Recent Development 11.3 AGTC 11.3.1 AGTC Company Detail 11.3.2 AGTC Business Overview 11.3.3 AGTC Gene Therapy for Age-related Macular Degeneration Introduction 11.3.4 AGTC Revenue in Gene Therapy for Age-related Macular Degeneration Business (2018-2023) 11.3.5 AGTC Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details

List of Tables Table 1. Global Gene Therapy for Age-related Macular Degeneration Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029 Table 2. Key Players of Subretinal Table 3. Key Players of Intravitreal Table 4. Global Gene Therapy for Age-related Macular Degeneration Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029 Table 5. Global Gene Therapy for Age-related Macular Degeneration Market Size by Region (US$ Million): 2018 VS 2022 VS 2029 Table 6. Global Gene Therapy for Age-related Macular Degeneration Market Size by Region (2018-2023) & (US$ Million) Table 7. Global Gene Therapy for Age-related Macular Degeneration Market Share by Region (2018-2023) Table 8. Global Gene Therapy for Age-related Macular Degeneration Forecasted Market Size by Region (2024-2029) & (US$ Million) Table 9. Global Gene Therapy for Age-related Macular Degeneration Market Share by Region (2024-2029) Table 10. Gene Therapy for Age-related Macular Degeneration Market Trends Table 11. Gene Therapy for Age-related Macular Degeneration Market Drivers Table 12. Gene Therapy for Age-related Macular Degeneration Market Challenges Table 13. Gene Therapy for Age-related Macular Degeneration Market Restraints Table 14. Global Gene Therapy for Age-related Macular Degeneration Revenue by Players (2018-2023) & (US$ Million) Table 15. Global Gene Therapy for Age-related Macular Degeneration Market Share by Players (2018-2023) Table 16. Global Top Gene Therapy for Age-related Macular Degeneration Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Therapy for Age-related Macular Degeneration as of 2022) Table 17. Ranking of Global Top Gene Therapy for Age-related Macular Degeneration Companies by Revenue (US$ Million) in 2022 Table 18. Global 5 Largest Players Market Share by Gene Therapy for Age-related Macular Degeneration Revenue (CR5 and HHI) & (2018-2023) Table 19. Key Players Headquarters and Area Served Table 20. Key Players Gene Therapy for Age-related Macular Degeneration Product Solution and Service Table 21. Date of Enter into Gene Therapy for Age-related Macular Degeneration Market Table 22. Mergers & Acquisitions, Expansion Plans Table 23. Global Gene Therapy for Age-related Macular Degeneration Market Size by Type (2018-2023) & (US$ Million) Table 24. Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Type (2018-2023) Table 25. Global Gene Therapy for Age-related Macular Degeneration Forecasted Market Size by Type (2024-2029) & (US$ Million) Table 26. Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Type (2024-2029) Table 27. Global Gene Therapy for Age-related Macular Degeneration Market Size by Application (2018-2023) & (US$ Million) Table 28. Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Application (2018-2023) Table 29. Global Gene Therapy for Age-related Macular Degeneration Forecasted Market Size by Application (2024-2029) & (US$ Million) Table 30. Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Application (2024-2029) Table 31. North America Gene Therapy for Age-related Macular Degeneration Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029 Table 32. North America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2018-2023) & (US$ Million) Table 33. North America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2024-2029) & (US$ Million) Table 34. Europe Gene Therapy for Age-related Macular Degeneration Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029 Table 35. Europe Gene Therapy for Age-related Macular Degeneration Market Size by Country (2018-2023) & (US$ Million) Table 36. Europe Gene Therapy for Age-related Macular Degeneration Market Size by Country (2024-2029) & (US$ Million) Table 37. Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029 Table 38. Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size by Region (2018-2023) & (US$ Million) Table 39. Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size by Region (2024-2029) & (US$ Million) Table 40. Latin America Gene Therapy for Age-related Macular Degeneration Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029 Table 41. Latin America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2018-2023) & (US$ Million) Table 42. Latin America Gene Therapy for Age-related Macular Degeneration Market Size by Country (2024-2029) & (US$ Million) Table 43. Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029 Table 44. Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size by Country (2018-2023) & (US$ Million) Table 45. Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size by Country (2024-2029) & (US$ Million) Table 46. RetroSense Therapeutics Company Detail Table 47. RetroSense Therapeutics Business Overview Table 48. RetroSense Therapeutics Gene Therapy for Age-related Macular Degeneration Product Table 49. RetroSense Therapeutics Revenue in Gene Therapy for Age-related Macular Degeneration Business (2018-2023) & (US$ Million) Table 50. RetroSense Therapeutics Recent Development Table 51. REGENXBIO Company Detail Table 52. REGENXBIO Business Overview Table 53. REGENXBIO Gene Therapy for Age-related Macular Degeneration Product Table 54. REGENXBIO Revenue in Gene Therapy for Age-related Macular Degeneration Business (2018-2023) & (US$ Million) Table 55. REGENXBIO Recent Development Table 56. AGTC Company Detail Table 57. AGTC Business Overview Table 58. AGTC Gene Therapy for Age-related Macular Degeneration Product Table 59. AGTC Revenue in Gene Therapy for Age-related Macular Degeneration Business (2018-2023) & (US$ Million) Table 60. AGTC Recent Development Table 61. Research Programs/Design for This Report Table 62. Key Data Information from Secondary Sources Table 63. Key Data Information from Primary Sources List of Figures Figure 1. Global Gene Therapy for Age-related Macular Degeneration Market Size Comparison by Type (2023-2029) & (US$ Million) Figure 2. Global Gene Therapy for Age-related Macular Degeneration Market Share by Type: 2022 VS 2029 Figure 3. Subretinal Features Figure 4. Intravitreal Features Figure 5. Global Gene Therapy for Age-related Macular Degeneration Market Size Comparison by Application (2023-2029) & (US$ Million) Figure 6. Global Gene Therapy for Age-related Macular Degeneration Market Share by Application: 2022 VS 2029 Figure 7. Monotherapy Case Studies Figure 8. Combination Therapy Case Studies Figure 9. Gene Therapy for Age-related Macular Degeneration Report Years Considered Figure 10. Global Gene Therapy for Age-related Macular Degeneration Market Size (US$ Million), Year-over-Year: 2018-2029 Figure 11. Global Gene Therapy for Age-related Macular Degeneration Market Size, (US$ Million), 2018 VS 2022 VS 2029 Figure 12. Global Gene Therapy for Age-related Macular Degeneration Market Share by Region: 2022 VS 2029 Figure 13. Global Gene Therapy for Age-related Macular Degeneration Market Share by Players in 2022 Figure 14. Global Top Gene Therapy for Age-related Macular Degeneration Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Therapy for Age-related Macular Degeneration as of 2022) Figure 15. The Top 10 and 5 Players Market Share by Gene Therapy for Age-related Macular Degeneration Revenue in 2022 Figure 16. North America Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million) Figure 17. North America Gene Therapy for Age-related Macular Degeneration Market Share by Country (2018-2029) Figure 18. United States Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million) Figure 19. Canada Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million) Figure 20. Europe Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million) Figure 21. Europe Gene Therapy for Age-related Macular Degeneration Market Share by Country (2018-2029) Figure 22. Germany Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million) Figure 23. France Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million) Figure 24. U.K. Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million) Figure 25. Italy Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million) Figure 26. Russia Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million) Figure 27. Nordic Countries Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million) Figure 28. Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million) Figure 29. Asia-Pacific Gene Therapy for Age-related Macular Degeneration Market Share by Region (2018-2029) Figure 30. China Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million) Figure 31. Japan Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million) Figure 32. South Korea Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million) Figure 33. Southeast Asia Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million) Figure 34. India Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million) Figure 35. Australia Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million) Figure 36. Latin America Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million) Figure 37. Latin America Gene Therapy for Age-related Macular Degeneration Market Share by Country (2018-2029) Figure 38. Mexico Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million) Figure 39. Brazil Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million) Figure 40. Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million) Figure 41. Middle East & Africa Gene Therapy for Age-related Macular Degeneration Market Share by Country (2018-2029) Figure 42. Turkey Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million) Figure 43. Saudi Arabia Gene Therapy for Age-related Macular Degeneration Market Size YoY Growth (2018-2029) & (US$ Million) Figure 44. RetroSense Therapeutics Revenue Growth Rate in Gene Therapy for Age-related Macular Degeneration Business (2018-2023) Figure 45. REGENXBIO Revenue Growth Rate in Gene Therapy for Age-related Macular Degeneration Business (2018-2023) Figure 46. AGTC Revenue Growth Rate in Gene Therapy for Age-related Macular Degeneration Business (2018-2023) Figure 47. Bottom-up and Top-down Approaches for This Report Figure 48. Data Triangulation Figure 49. Key Executives Interviewed

RetroSense Therapeutics REGENXBIO AGTC